Advertisement
IMNM vs NRIX
Which Stock Would AI Choose? Immunome (IMNM) vs. Nurix Therapeutics (NRIX) Stock Comparison
Key Takeaways
- IMNM is a clinical-stage oncology company whose shares have pulled back sharply in recent weeks even as it advanced its lead desmoid tumor program toward a potential approval decision.
- NRIX has delivered strong momentum and a sharp swing to profitability, driven largely by a large collaboration payment from Roche rather than product sales.
- The two companies compete in different niches of biotechnology: Immunome is centered on antibody-drug conjugates (ADCs), while Nurix specializes in targeted protein degradation (TPD).
- Relative performance diverged recently, with NRIX showing stronger trend consistency while IMNM traded through a period of consolidation and weakness.
- Both stocks carry elevated clinical, regulatory, and financing risk typical of pre-commercial and early-commercial biotech names.
Introduction
Investors comparing IMNM and NRIX are weighing two high-growth, high-risk biotechnology stories with very different catalysts. This stock comparison is relevant for traders and investors who follow oncology and autoimmune drug development and want to understand how market positioning, funding, and pipeline milestones shape relative performance. Both companies are unprofitable on a recurring basis, yet both have attracted substantial institutional interest. Understanding their distinct business models, momentum profiles, and risk factors can help readers assess which name currently aligns with their own objectives in this volatile sector.
IMNM Overview and Recent Performance
IMNM, Immunome, Inc., is a biotechnology company focused on discovering and developing antibody-drug conjugates (ADCs) and other oncology therapies. Its most advanced asset, varegacestat, targets desmoid tumors, a rare soft-tissue condition. Following positive Phase 3 RINGSIDE trial results, the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration, with a PDUFA (Prescription Drug User Fee Act) target action date set for April 2027. The company also plans a Marketing Authorization Application (MAA) in Europe.
Despite these milestones, IMNM shares experienced notable selling pressure in recent weeks, with the 30-day return down roughly 28% at points even as its one-year and multi-year returns remained positive. This pullback reflects profit-taking and broader biotech sector caution, offset by sustained bullish analyst coverage and recent regulatory momentum, including FDA clearance of an investigational new drug application for its IM-1340 ADC program. Sentiment remains divided between long-term pipeline optimism and near-term execution and financing concerns.
NRIX Overview and Recent Performance
NRIX, Nurix Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing targeted protein degradation (TPD) medicines for cancer and autoimmune diseases. Its lead candidate, bexobrutideg, is a BTK (Bruton's tyrosine kinase) degrader being studied in B-cell malignancies such as chronic lymphocytic leukemia (CLL). The company recently began dosing patients in a registrational Phase 3 trial comparing bexobrutideg with an existing therapy in relapsed/refractory CLL.
NRIX shares have shown pronounced strength, with a one-year return near 150% and year-to-date gains well ahead of the broader market. The primary catalyst was a collaboration with Roche, which included a $700 million upfront payment and potential total payments of up to $2.3 billion. The resulting license revenue drove a dramatic swing to reported profitability in the most recent quarter, lifting cash to roughly $1.1 billion and extending the company's runway into the second half of 2029. While analysts broadly raised price targets, some note that reliance on partner payments introduces concentration and execution risk.
Trending AI Robots
For traders who prefer a data-driven approach, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and statistics. Because market conditions change, only the bots considered best suited to the current environment earn a place in this curated section. The result is a focused list where users can review key metrics and decide which approaches warrant closer study. Exploring the Trending AI Robots section is a practical way to see how algorithmic tools are currently navigating names such as these.
Head-to-Head Comparison
The two companies occupy different corners of biotechnology. IMNM is centered on ADC-based oncology, with a near-term commercial catalyst tied to a single lead asset in a rare disease. Its value is concentrated in the varegacestat approval timeline and the pace of desmoid tumor market adoption. NRIX operates a broader platform built on protein degradation, with multiple big-pharma partners providing funding and validation across oncology and autoimmune indications.
On funding and balance-sheet positioning, NRIX currently holds a stronger cash position and extended runway, aided by non-dilutive collaboration payments. Immunome remains pre-revenue and more dependent on external capital and successful regulatory execution. On recent momentum, NRIX has demonstrated greater trend consistency and relative strength, while IMNM has traded through a corrective phase despite a pipeline of advancing candidates. Risk profiles differ as well: IMNM carries concentrated single-asset and regulatory risk, while NRIX faces partner-concentration risk and the challenge of converting one-time payments into durable product revenue.
Tickeron AI Verdict
Based on observable factors such as trend consistency, funding visibility, catalyst quality, and relative positioning, Tickeron's AI would likely favor NRIX in the current environment. The stock's stronger recent momentum, substantial cash position, and progressing late-stage pipeline suggest a more stable technical and fundamental setup. In contrast, IMNM shows compelling long-term catalysts but currently displays weaker short-term trend signals amid a corrective phase. This is a probabilistic assessment grounded in recent data rather than a definitive forecast, and relative positioning could shift as new clinical, regulatory, and financing developments emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMNM is a StrongBuy and NRIX is a Hold.
IMNM's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for IMNM turned positive on October 22, 2026. Looking at past instances where IMNM's MACD turned positive, the stock continued to rise in 42 of 45 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMNM's RSI Oscillator exited the oversold zone, 31 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 64 cases where IMNM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
Following a +1.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNM advanced for three days, in 235 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
IMNM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
IMNM moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IMNM crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for IMNM entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.950) is normal, around the industry mean (2.973). P/E Ratio (-7.217) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. IMNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NRIX's Stochastic Oscillator stays in overbought zone for 5 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for NRIX moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 23 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The 10-day moving average for NRIX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NRIX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NRIX entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on NRIX as a result. In 68 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for NRIX just turned positive on October 14, 2026. Looking at past instances where NRIX's MACD turned positive, the stock continued to rise in 32 of 40 cases over the following month. The odds of a continued upward trend are 80%.
NRIX moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in 204 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. NRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.575) is normal, around the industry mean (2.973). P/E Ratio (-7.373) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (68.493) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IMNM | NRIX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 65 | 36 | |
P/E GROWTH RATING 1..100 | 23 | 56 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NRIX's Valuation (39) in the null industry is in the same range as IMNM (63). This means that NRIX’s stock grew similarly to IMNM’s over the last 12 months.
NRIX's Profit vs Risk Rating (100) in the null industry is in the same range as IMNM (100). This means that NRIX’s stock grew similarly to IMNM’s over the last 12 months.
NRIX's SMR Rating (98) in the null industry is in the same range as IMNM (98). This means that NRIX’s stock grew similarly to IMNM’s over the last 12 months.
NRIX's Price Growth Rating (36) in the null industry is in the same range as IMNM (65). This means that NRIX’s stock grew similarly to IMNM’s over the last 12 months.
IMNM's P/E Growth Rating (23) in the null industry is somewhat better than the same rating for NRIX (56). This means that IMNM’s stock grew somewhat faster than NRIX’s over the last 12 months.
| IMNM | NRIX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Momentum ODDS (%) | N/A | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 86% |
| Advances ODDS (%) | 2 days ago 82% | 4 days ago 82% |
| Declines ODDS (%) | 10 days ago 86% | 2 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMNM’s FA Score shows that 1 FA rating(s) are green while NRIX’s FA Score has 0 green FA rating(s).
- IMNM’s FA Score: 1 green, 4 red.
- NRIX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMNM’s TA Score shows that 5 TA indicator(s) are bullish while NRIX’s TA Score has 4 bullish TA indicator(s).
- IMNM’s TA Score: 5 bullish, 4 bearish.
- NRIX’s TA Score: 4 bullish, 6 bearish.
Price Growth
IMNM (@Biotechnology) experienced а +4.94% price change this week, while NRIX (@Biotechnology) price change was +2.24% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.31%. For the same industry, the average monthly price growth was -16.25%, and the average quarterly price growth was -16.62%.
Reported Earning Dates
IMNM is expected to report earnings on Nov 05, 2026.
NRIX is expected to report earnings on Feb 17, 2027.
Industries' Descriptions
@Biotechnology (+1.31% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IMNM and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMNM has been loosely correlated with KYTX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNM jumps, then KYTX could also see price increases.
| Ticker / NAME | Correlation To IMNM | 1D Price Change % | ||
|---|---|---|---|---|
| IMNM | 100% | +1.44% | ||
| KYTX - IMNM | 59% Loosely correlated | -1.88% | ||
| SLDB - IMNM | 54% Loosely correlated | -3.43% | ||
| EDIT - IMNM | 51% Loosely correlated | -0.80% | ||
| FDMT - IMNM | 49% Loosely correlated | -6.10% | ||
| MGTX - IMNM | 49% Loosely correlated | -0.91% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| REIX | 29.25 | 0.57 | +2.00% |
| NYLIM CBRE Real Estate & Infrastructure ETF (REIX) | |||
| EVX | 40.72 | 0.56 | +1.39% |
| VanEck Environmental Services ETF (EVX) | |||
| TSIC | 24.99 | N/A | N/A |
| Truth Social American Icons ETF Amrn Icons ETF (TSIC) | |||
| XDTE | 37.72 | -0.62 | -1.62% |
| Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) | |||
| ASA | 48.99 | -2.51 | -4.87% |
| ASA Gold AND Precious Metals Limited | |||